ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TTNP Titan Pharmaceuticals Inc

6.94
0.00 (0.00%)
Pre Market
Last Updated: 04:16:56
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 6.39
Ask Price 9.42
News -
Day High

Low
5.00

52 Week Range

High
16.59

Day Low
Company Name Stock Ticker Symbol Market Type
Titan Pharmaceuticals Inc TTNP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 6.94 04:16:56
Open Price Low Price High Price Close Price Prev Close
6.94
Trades Volume Avg Volume 52 Week Range
0 0 - 5.00 - 16.59
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.94 USD

Titan Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.42M 781.50k - 184k -5.57M -7.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Titan Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TTNP Message Board. Create One! See More Posts on TTNP Message Board See More Message Board Posts

Historical TTNP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.437.096.426.726820.517.93%
1 Month6.437.21676.086.461,6890.517.93%
3 Months6.649.076.087.074,8840.304.52%
6 Months5.4369.3525.007.2619,3581.5027.67%
1 Year15.2016.595.009.7841,978-8.26-54.34%
3 Years52.2062.005.0021.16149,021-45.26-86.70%
5 Years834.001,176.005.00134.404,134,608-827.06-99.17%

Titan Pharmaceuticals Description

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Your Recent History

Delayed Upgrade Clock